IDEAYA Biosciences Inc
For the period ended Mar 31, 2025. Filed May 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| ExhibitNumber · Exhibit Description · Incorporated by Reference · FiledHerewith | |||||
|---|---|---|---|---|---|
| Form · Date · Number | |||||
| 3.1 | Amended and Restated Certificate of Incorporation. | 8-K | 5/28/2019 | 3.1 | |
| 3.2 | Amended and Restated Bylaws. | 8-K | 5/28/2019 | 3.2 | |
| 4.1 | Reference is made to Exhibits 3.1 through 3.2. | ||||
| 4.2 | Form of Common Stock Certificate. | S-1/A | 5/13/2019 | 4.2 | |
| 4.3 | Description of Common Stock. | 10-K | 2/18/2025 | 4.3 | |
| 4.4 | Form of April 2023 Pre-funded Warrant. | 8-K | 4/27/2023 | 4.1 | |
| 4.5 | Form of October 2023 Pre-funded Warrant. | 8-K | 10/27/2023 | 4.1 | |
| 4.6 | Form of July 2024 Pre-funded Warrant. | 8-K | 7/11/2024 | 4.1 | |
| 10.1# | Non-Employee Director Compensation Program. | X | |||
| 10.2#† | Employment Agreement by and between IDEAYA Biosciences, Inc. and Andres Ruiz Briseno. | X | |||
| 10.3#† | Employment Agreement Addendum by and between IDEAYA Biosciences, Inc. and Douglas Snyder. | X | |||
| 10.4† | Clinical Study Collaboration and Supply Agreement by and between IDEAYA Biosciences, Inc. and Gilead Sciences, Inc. dated February 12, 2025. | X | |||
| 19.1† | Insider Trading Compliance Policy. | X | |||
| 31.1 | Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | |||
| 31.2 | Certification of the Principal Financial and Accounting Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X |
| 32.1* | Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | X |
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | X |
| 101.SCH | Inline XBRL Taxonomy Extension Schema with Embedded Linkbase Documents. | X |
| 104 | Cover Page Interactive Data File (embedded with the Inline XBRL document). | X |
† Portions of this exhibit have been omitted pursuant to Regulation S-K, Item 601(b)(10) or certain schedules and attachments to this exhibit have been omitted pursuant to Regulation S-K, Item 601(a)(5). Such omitted information is not material and would likely cause competitive harm to the registrant if publicly disclosed.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.